Persistence

Global Internal Beam & Systemic Radiation Therapy Devices Market Is Expected to Reach $1,032.4 Million in 2017, Growing at a CAGR of 4.6% from 2012 to 2017.

Persistence Market Research is pleased to announce the launch of its “Internal Beam & Systemic Radiation Therapy Devices (Seeds, Applicators & Afterloaders, Iobenguane (I-131, Samarium (Sm-153, Rhenium (Re-186), Erbium (Er-169, Yttrium (Yt-90), Low Dose Rate (LDR), High Dose Rate (HDR) and Cancer Applications) Market Assessment Report - Global Size, Share, Competitive Landscape, Future Prospects and Forecast from 2013-2017”, according to which the global internal beam & systemic radiation therapy devices market was worth $790.6 million in 2011 and is expected to reach $1,032.4 million in 2017, growing at a CAGR of 4.6% from 2012 to 2017.

 
Repost This

San Mateo, CA -- (SBWIRE) -- 01/14/2014 -- For the treatment of cancer, radiotherapy has shifted the paradigm towards safer and quicker treatment procedures, with the market witnessing dramatic technological evolutions since last few years. Compared to external beam therapy market segment, internal beam therapy and systemic radiation therapy contribute less percentage to the market. However, these market segments ensure a holistic growth of the entire radiotherapy market. In the systemic radiation therapy market, due to substantial improvement in the survival rate of thyroid cancer patients, I-131 is the most preferred isotope to other sources.

Please click here to view the report contents in detail.

Continuous technological revolution has greatly helped in driving the internal beam radiation therapy devices market, with low dose rate (LDR) brachytherapy technology pulling the market considerably. In addition, efficacious treatment with better safety and clinical outcome has driven these markets. In coming years, owing to its efficient treatment outcomes compared to existing technologies, high dose rate (HDR) brachytherapy technology is expected to grow at a higher pace and contribute majorly to the radiotherapy market. Moreover, the application market for internal beam and systemic therapy devices is principally driven by increasing rate of cancer incidences worldwide, thereby creating a huge unmet need for better treatment options.

Permanent or low dose rate (LDR) brachytherapy seeds are the dominating seeds in this market. These include I-125, Pd-103 and Cesium-131 (Cs-131) which are the popular implants in the LDR brachytherapy market. Though Cs-131 has better efficiency compared to the other two isotopes, market preference for this isotope has been very low till date. In the current scenario, I-125 isotope is considered as the most cost-effective isotope that entails maximum growth in its total value and volume compared to other leading radioisotopes.

Please click here to view the report contents in detail.

In terms of geography, North America has been the major market for internal beam and systemic therapies, as it has hugely benefitted from varied reimbursement policies for physicians and patients, evenly supported by the respective government, which clearly gives impetus to newer technologies in the market. Systemic radiation therapy market is still small in North America, where major radiopharmaceutical companies are imparting education and awareness about the benefits of this therapy over other therapies.

For the internal beam radiation therapy devices market, Eckert & Ziegler Bebig SA, Theragenics, Corp., Oncura, Inc., and iCAD, Inc. represent the major players while in the systemic radiation therapy market, IsoRay, Inc., POLATOM, MDS Nordion, and Australian Nuclear Science and Technology Organisation (ANSTO) form the most prominent players, although the overall radiotherapy market is hugely fragmented with a large number of players.

The global internal beam and systemic radiation therapy devices market is segmented as follows:
Global internal beam radiation therapy devices market, by products
- Seeds
- Applicators & Afterloaders
- Electronic Brachytherapy
Global systemic radiation therapy devices market, by products
- Iobenguane (I-131)
- Samarium (Sm-153)
- Rhenium (Re-186)
- Erbium (Er-169)
- Yttrium (Yt-90)
- Others
Global internal beam radiation therapy devices market, by applications
- Prostate Cancer
- Gynecological Cancer
- Breast Cancer
- Cervical Cancer
- Penile Cancer
- Other Cancers (Lung, Head & Neck and Esophageal Cancers)
Global internal beam radiation therapy devices market, by technology
- Low Dose Rate (LDR)
- High Dose Rate (HDR)
- Global internal beam radiation therapy devices market, by geography
North America
Europe
Asia
Rest of the World (RoW)

Please click here to view other medical device related reports.

About Persistence Market Research
Persistence Market Research is a specialized team of analysts and consultants in healthcare domain. Our business intelligence and market research capabilities span over multiple sub-industries under healthcare such as Medical Device, Healthcare-IT, Biotechnology and Pharmaceuticals.

Our understanding about the market persuades us to share the right information with the right reader and save time on decision making. In today’s competitive market world, the decision making of our clients does not merely depend upon their wishes but also on technological advancements and what their competitors are doing or plan to do. This is where we come in existence, with extensive healthcare domain knowledge and statistical analysis background helping our clients with quick and accurate market information.

Contact:
Mr. Reilly Jay
845 N Humboldt Street,
Suite 1015,
San Mateo, CA 94401
United States
Tel: +1-650-242-4491
US/Canada Toll Free Number: 1-877-667-4748
E-mails:
jay@persistencemarketresearch.com
sales@persistencemarketresearch.com
Website: http://www.persistencemarketresearch.com?